Roche's MS game-changer nabs FDA green light by Carly Helfand Tuesday, March 28, 2017 The new multiple sclerosis med Roche has been anticipating—and the market shake-up other drugmakers have been dreading—is here.
Novartis could snag a blockbuster MS market all for itself by Carly Helfand Monday, September 19, 2016 Novartis’ multiple sclerosis pill Gilenya may soon be in trouble on the generics front. But the Swiss drugmaker has another MS product in the works that it thinks could break the billion-dollar sales mark.
